Previous 10 | Next 10 |
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approxim...
2023-11-15 13:12:41 ET More on Materials Sector XLB: The ETF That Beat The S&P 500 XLB Is A Hold Considering Risks Of Global Deflation Led By China XLB: Ultimately A Chemicals Play With An Unclear Outlook Materials Sector Weekly Round-up: Cabot at t...
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023. Mesoblast Chief Executive Silviu Itescu said: ...
2023-10-25 12:24:52 ET Summary Mesabi Trust's near-term value depends on the actions of Cleveland-Cliffs Inc., which operates the Northshore iron ore mine. Cleveland-Cliffs idled the Northshore mine in 2022 and restarted it in Q2 2023, but CEO Goncalves has threatened to use it as...
2023-10-18 14:08:50 ET Summary Mesabi Trust distributions were scrapped because Cleveland-Cliffs temporarily idled its mine. Iron ore demand could benefit from China's construction sector stimulus. Normalized annualized distributions per unit from Mesabi Trust could be as high...
2023-10-13 16:15:01 ET More on Mesabi Trust Financial information for Mesabi Trust For further details see: Mesabi Trust declares $0.35 dividend
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that independent Director Jane Bell AM has been appointed Chair of the Mesoblast Board Audit and Risk Committee. Ms Bell...
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the path to approval for its lead-product candidate remestemcel-L in the treatment of pediatric and adult st...
Farmer Brothers Company (FARM) is expected to report $-0.61 for Q4 2023 Aspen Group Inc. (ASPU) is expected to report for Q1 2023 Kaspien Holdings Inc. (KSPN) is expected to report for Q1 2024 AGC Inc ADR (ASGLY) is expected to report for Q2 2023 Shimano Inc. ADR (SMNNY) is expect...
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming miles...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2024. Mesoblast Chief Executive Silviu Itescu said: ȁ...
HomeStreet Inc. (HMST) is expected to report $-0.06 for Q1 2024 Kforce Inc. (KFRC) is expected to report $0.58 for Q1 2024 Sun Communities Inc. (SUI) is expected to report $1.16 for Q1 2024 Mynaric AG (MYNA) is expected to report for Q4 2023 Albany International Corporation (AIN) ...
Bank of Hawaii Corporation (BOH) is expected to report $0.92 for Q1 2024 Brown & Brown Inc. (BRO) is expected to report $1.07 for Q1 2024 Independent Bank Group Inc (IBTX) is expected to report $0.57 for Q1 2024 Burnham Holdings Inc - Class A (BURCA) is expected to report for Q1 2...